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INTRODUCTION 
           Cerebrovascular accident or CVA or stroke forms the major bulk 
of the burden of the neurological conditions that a physician sees in his 
day to day practice. There are many synonyms to stroke like CVA or 
cerebrovascular accident or brain attack etc. 
           A cerebrovascular accident is defined as an sudden onset of a 
neurologic deficit due to a focal vascular cause. This can be due to 
ischaemia or haemorrhage. 
           Cerebrovascular accident comprises some of the most devastating 
disorders. There are 15 million people worldwide who suffer a stroke 
each year.  According to the statistics given by World Health 
Organization (WHO),  in people aged more than 60 years cerebrovascular 
accident is the 2nd leading cause of death and in people aged between 15 
to 59 years it is the 5th cause of death. Every year, nearly six million 
people  die from CVA worldover. This summarises the great burden that 
world faces due to CVA. The problem is even on the rising trend with the 
world facing a rapid level of rise in the incidence of CVA mainly 
attributable to the high rise in the level of the contributary risk factors like 
hypertension, diabetes, obesity, smoking etc. 
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           C-reactive protein (CRP) is an acute phase protein that rises in 
many conditions of inflammation. High levels of CRP and other 
inflammatory markers have been found in conditions of atherosclerosis. 
High levels of CRP have been linked to various vascular events like 
cerebrovascular accident and myocardial infarction through various 
studies. 
              In CARE study high levels of CRP was correlated to recurrent 
events or even death. Framingham study linked CRP to Tansient 
ischaemic attack or CVA .Cardiovascular health study found an 
association between CRP and carotid intima media thickness. 
           Ischaemic CVA is found to have a higher level of CRP. The 
pathogenic mechanism behind it is said to be due to the inflammation and 
tissue damage caused by the ischaemia of brain tissue. Many animal 
studies show that CRP can cause a secondary damage to brain perhaps by 
activating complement pathway. However in case of humans we are not 
sure if this kind of secondary brain damage is caused by CRP or not.      
          Hence measuring CRP may be of clinical relevance in ischaemic 
stroke. This test readily available and easily measured in most of the 
hospitals.  Hence I chose this study to determine the prognostic value of 
CRP measured in acute ischemic stroke for poor functional outcome and 
death in a sample of patients with acute ischemic stroke.                     
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AIMS AND OBJECTIVES 
 
 To evaluate the role of serum CRP as a biomarker for predicting 
severity and short term outcome in acute ischaemic stroke. 
 
 To assess the severity of stroke using NIHSS(National Institute of 
Health Stroke Scale) and outcome using mRS(modified Rankin 
Scale) and BI(Barthel Index)  
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REVIEW OF LITERATURE 
  Cerebrovascular accident is one of the most common neurologic 
disease encountered in clinical practice. It is defined as sudden 
occurrence of focal neurological deficit. It is classified broadly into 
ischaemic and haemorrhagic .ischaemic CVA occurs due to occlusion of 
blood vessel supplying the brain. Haemorrhagic CVA occurs due to 
haemorrhage into the brain matter or subarachnoid space or ventricles. 
      Ischaemic CVA due to blockage of blood supply to the brain 
causes ischaemia and finally infarction leading to death of neurons . 
Proper  history taking and clinical examination helps to differentiate the 
two types of cerebrovascular accident. Clinical examination helps to find 
the region of brain effected. 
The usual causes associated with this type of cerebrovascular accident is :- 
1) atherothrombosis 
2) embolism 
However there are many other causes apart from the usual 
associated with cerebrovascular accident. Another entity associated 
include Transient Ischaemic Attack(TIA). In this the neurological deficit 
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will be temporary and patient clinically recovers without any deficit 
within 24 hours without any imaging evidence.  
Haemorrhagic cerebrovascular accident is usually caused by 
hypertension, coagulopathies, vascular malformations, trauma, 
haemorrhage into ischaemic area. Subarachnoid haemorrhage is most 
commonly caused by rupture of aneurysm, rarely by arterio venous 
malformations. 
In case of embolic CVA the deficit is maximum at its onset. 
Thrombotic CVA evolves slowly. Haemorrhagic CVA may be static or 
progressive. There may be many variations to this. 
   The main aims while we evaluate a stroke patient is:- 
1) Confirm diagnosis 
2) Pathophysiology 
3) If acute treatment is needed or not 
4) Prevention 
Over the years better imaging modality has been an added boon to 
our diagnosis and management of CVA. However a good understanding 
of the nervous system and a sound clinical knowledge is a must especially 
in cases where imaging may not be contributory or in third world 
countries where the imaging facilities may not be that readily available. 
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EPIDEMIOLOGY 
From the available data1, in US cerebrovascular accident is the 
third most common cause of death after heart disease and cancer. 2Out of 
7 lakh cases every year 6  lakh is of ischaemic and 1 lakh is haemorrhagic 
cerebrovascular accident. This shows that ischaemic CVA is more 
common than haemorrhagic one.  
According to World Health Organisation3 and other experts 
cerebrovascular accident claims 6.2 million lives every year. In 2008,17.3 
million people died from cerebrovascular diseases which is 30% of global 
deaths. Of these deaths 7.3 million were due to coronary heart disease and 
6.2 million were due to cerebrovascular accidents.  
    Coming to Indian scenario4, the updated data in 2012 shows that 
the rate of cerebrovascular accidents ranges from 84 per 1 lakh to 262 per 
1 lakh in rural areas and between 334 per 1 lakh to 424 per 1 lakh in 
urban areas. However due to various reasons the effective diagnosis and 
treatment of various modifiable risk factors and the disease , better 
imaging modalities , intervention techniques have reduced the mortality 
considerably over many years. But the residual disability still remains a 
problem and hence the morbidity is still a matter of concern. 
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RISK FACTORS FOR STROKE 
  Over 300 risk factors5 have been identified for cerebrovascular 
accidents and coronary artery disease. Broadly they can be divided into 
modifiable and non-modifiable risk factors . 
MODIFIABLE RISK FACTORS 
• Hypertension 
• Atrial fibrillation  
• Diabetes mellitus 
• Smoking 
• Hyperlipidemia 
• Obesity 
• Stress 
• Drugs-OCPs 
• Unhealthy diet- low potassium, low fruit and vegetable intake, high 
saturated fat intake 
• Alcohol use 
• Hyperhomocysteinemia 
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NON MODIFIABLE RISK FACTORS 
• Advancing age – risk of stroke doubles with every decade after  
55 years. 
• Family history 
• Gender- risk of stroke is higher in men but lifetime risk of stroke is 
higher in women. 
• Ethinicity or race – higher risk in Blacks, some Hispanics, 
Americans, Chinese  and Japanese populations. 
 
CAUSES OF STROKE 
1. Atherosclerotic thrombosis 
2. Transient ischemic attacks 
3. Embolism 
4. Hypertensive hemorrhage 
5. Ruptured or unruptured saccular aneurysm or AVM 
6. Arteritis 
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a. Meningovascular syphilis, arteritis secondary to pyogenic 
and tuberculous meningitis, rare infective types (typhus, 
schistosomiasis, malaria, mucormycosis, etc.) 
b. Connective tissue diseases (polyarteritis nodosa, lupus 
erythematosus), necrotizing arteritis. Wegener arteritis, temporal 
arteritis, Takayasu disease, granulomatous or giantcell arteritis of 
the aorta, and giant-cell granulomatous angiitis of cerebral arteries 
7. Cerebral thrombophlebitis: secondary to infection of ear, 
paranasal sinus, face, etc.; with meningitis and subdural empyema; 
debilitating states, postpartum, postoperative, cardiac failure, 
hematologic disease (polycythemia, sickle cell disease), and of 
undetermined cause 
8. Hematologic disorders: anticoagulants and thrombolytics, 
clotting factor disorders, polycythemia, sickle cell disease, 
thrombotic thrombocytopenic purpura, thrombocytosis, 
intravascular lymphoma, etc. 
9. Trauma and dissection of carotid and basilar arteries 
10. Amyloid angiopathy 
11. Dissecting aortic aneurysm 
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12. Complications of arteriography 
13. Neurologic migraine with persistent deficit 
14. With tentorial, foramen magnum, and subfalcial herniations 
15. Miscellaneous types: fibromuscular dysplasia, with local 
dissection of carotid, middle cerebral, or vertebrobasilar artery, x-
irradiation, unexplained middle cerebral infarction in closed head 
injury, pressure of unruptured saccular aneurysm, complication of 
oral contraceptives 
16. Undetermined cause in children and young adults: moyamoya 
disease and others 
 
PATHOPHYSIOLOGY OF ISCHAEMIC STROKE 
In ischaemic cerebrovascular accident there is occlusion to the 
blood supply to the brain. The amount of blood flow that is reduced as a 
result of blockage varies from person to person depending on the vascular 
anatomy, site of block and blood pressure. 6When the blood flow to brain 
is reduced to zero it causes death of brain tissue within 4 to 10 minutes. If 
the blood flow is reduced to less than 16- 18 ml/ 100 g tissue per minute 
then infarction occurs in an hour. If less than 20 ml / 100 g tissue per 
minute then ischaemia occurs without infarction but if its prolonged to 
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several hours or days then it may lead to infarction. If the blood supply is 
restored to the brain at the right time, i.e before ishaemia leads to 
infarction then the patient may experience only transient symptoms. 
Ischaemic penumbra is a region surrounding infarction which is 
ischaemic. Hence this region is only reversibly damaged and we aim to 
restore the blood supply to this area as soon as possible to protect 
maximum salvageable brain tissue. Ischaemic penumbra can be 
visualised by imaging modalities like CT or MRI. 
 
Infarction of brain tissue can occur by:- 
1) Necrosis – caused by greater degree of ischaemia 
2) Apoptosis – caused by lesser degree of ischaemia 
Apoptosis occurs over days to weeks. Both hyperglycemia and 
hyperthermia have been found to worsen the brain damage. Hence 
we should avoid both. 
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ETIOLOGY 
Most common etiological factors are Atherothrombosis and 
Embolism. 
ATHEROTHROMBOSIS 
Half of the cases of thrombotic cerebrovascular accident has a 
preceding Transient Ischaemic Attack. It has an intermittent progression. 
Atheromatous plaque usually form at the region of branching or at curves 
of arteries.  Most common sites are :- 
1) Internal carotid artery at its origin 
2) Vertebral artery – cervical part and at the junction forming 
basilar artery 
3) Middle cerebral artery – stem or bifurcation 
4) Posterior cerebral artery – proximal part 
5) Anterior cerebral artery – proximal part 
Atheroma may develop in the Common Carotid Artery or Vertebral 
Artery at its origin from Aorta but it rarely cause symptoms due to 
adequate collaterals. The atheroma may cause occlusion of the artery and 
cause symptoms or it may cause an embolism. More than 90% occlusion 
of lumen of Carotid artery is associated with high incidence of stroke. 
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EMBOLISM 
Embolic cerebrovascular accident develops abruptly usually 
without Transient Ischaemic Attack. Most frequently it is due to an 
embolus arising from the heart called cardioembolism. It may also be 
from another occluded artery like carotid or vertebral artery. It may be a 
paradoxical embolus or it may be an embolus from vegetation in heart i.e 
infective endocarditis. Other rare ones may be fat, tumor cells (atrial 
myxoma), fibrocartilage, air, amniotic fluid. There is no time for 
collaterals to develop after embolisation, hence symptoms develop 
depending on the blood vessel occluded. 
Framingham Heart Study showed there is 6 times risk for 
cerebrovascular accident in patients with Atrial fibrillation.7Scoring 
systems like CHADS2 and CHA2DA2-VASc have been developed to 
predict the risk of stroke with atrial fibrillation and to start 
anticoagulation in such patients. 
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TRANSIENT ISCHAEMIC ATTACK 
TIA is occurrence of focal neurological deficit temporarily. Patient  
recovers within 24 hours, and it usually lasts for more than 1 hour. The 
etiology of TIA is same as that of cerebrovascular accident, i.e embolism 
or thrombosis. The significance of TIA clinically is because of the fact 
that it can usually precede stroke. Hence sometimes admitting a patient 
with TIA may be of use for even thrombolysis at the right time. 8Studies 
have shown that 10-15% TIA develop into stroke within 3 months. 
However most patients with TIA develop stroke within 2 days. Risk 
scores have been developed to predict the occurrence of stroke after TIA. 
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Prevention is the goal. Various studies are there that studied the 
prevention of occurrence of CVA after TIA. Many of these recommend 
aspirin in combination with clopidogrel. 
 
SCORE 
2 DAY RISK FOR 
STROKE 
RECURRENCE IN  
90 DAYS 
0 TO 3 LOW 1% 
4 TO 5 MODERATE 4.1% 
6 TO 7 HIGH 8.1% 
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STROKE SYNDROMES 
 A careful and precise understanding of the blood supply of the 
brain may help to delineate the area of occlusion in cerebrovascular 
accident. 
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STROKE SEVERITY 
Stroke can be assessed using NIHSS9 (National Institute of Health 
Stroke Scale). It divides the stroke into mild moderate and severe based 
on the scores obtained. 
 
MILD   –  NIHSS 0 TO 7 
MODERATE  –  NIHSS 8 TO 14 
SEVERE   –  NIHSS MORE THAN 14 
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NIHSS 
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OUTCOME 
Various scoring systems are available for the measurement of 
outcome in cerebrovascular accident. Many such scores10 are used for 
study and research purpose as they help to quantify patients disability and 
morbidity for better understanding of the outcomes. Examples of such 
scoring systems include – Modified Rankin score (MRS) and Barthel 
Index (BI). A score of more than 2 in MRS and less than 95 in BI are 
generally considered poor.   
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IMAGING 
CT BRAIN 
It helps to immediately differentiate ischaemic CVA from 
Haemorrhagic one. The biggest advantage is that it can be done 
immediately at great speed and is readily available in government 
hospitals too in our country. This is also a very cost effective imaging 
modality available for cerebrovascular accident. Hence it is the imaging 
modality of choice in stroke.  However the problem with this technique is 
that infarct may not be visible in CT film during the first few hours after 
the event. It usually takes 24 to 48 hours to be visible in the film. 
Posterior circulation ischaemic may be missed due to bony artifice. 
Another disadvantage of the imaging is the hazard of being exposed to 
harmful X Ray radiations.  
    Contrast enhanced CT is another option available. It helps to 
delineate the venous structures of brain better. Hence it may be of good 
use in diagnosing cortical venous thrombosis.  
    CT angiography is also of use. It helps to visualise arterial 
structure. Hence we can directly see the region of blood vessel that is 
blocked. By correlating with the vascular blood supply of brain we will 
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know the area of brain that is infarcted. This may be use in finding the 
ischaemic penumbra and salvaging it. 
 
MRI BRAIN 
    This is a more precise and better imaging modality compared to 
CT. The images produced are of better quality and clarity. Even minor 
abnormalities and infarcts, hemorrhages are easily picked up. Diffusion 
weighted imaging and Fluid attenuated inversion recovery (FLAIR) are 
very sensitive to pick up very early abnormalities. 
MR angiography is very useful one to detect the abnormalities of 
cerebral blood vessels like occlusion or aneurysms. 
    Iron Sensitive Imaging (ISI) is sensitive for detecting microbleeds. 
    However the disadvantage of MRI is that it is not that readily 
available in all hospitals, it is time consuming hence cannot be done on an 
emergency basis. If the patient is unstable then it may not be possible to 
do an MRI urgently. If patients have claustrophobia then it may not be 
possible to do an MRI. Most importantly MRI is a very costly imaging 
modality and in a country like our it may not be afforded by all patients. 
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CEREBRAL ANGIOGRAPHY 
    X Ray angiography is the gold standard technique to detect 
cerebral atherosclerosis and other abnormalities like vasospasm, 
aneurysm, etc. however nowadays this modality is rarely used as we have 
CT angiography and MR angiography, which are less cumbersome and 
provides better image. 
 
ULTRASOUND TECHNIQUES 
Duplex ultrasound can detect flow velocity. Transcranial Doppler 
may of use in assessing the blood flow in cerebral blood vessels, it may 
aid in thrombolysis too. It also helps to visualize the origin of carotid 
artery and its caliber which may be of use in intervention. 
 
PERFUSION TECHNIQUES 
    Xenon CT and PET scan may be used. However both are costly 
techniques which is currently in use only for research purposes. Single 
photon emission computerized tomography (SPECT) , MR perfusion 
techniques may also be used to assess perfusion. 
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TREATMENT 
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APPROACH TO A STROKE PATIENT 
The first and foremost step in the management would be to 
stabilize the patient as in any other condition. Make sure that the Airway , 
Breathing and Circulation (ABC) is maintained. Once the patient is stable 
we have to proceed with CT brain to differentiate between ischaemic and 
haemorrhagic stroke. 
 
SUPPORTIVE MEASURES 
The basic goal is to maintain as much as cerebral blood flow as 
possible especially to the salvageable ischaemic penumbra. We usually 
maintain the blood pressure at higher level as the rise in blood pressure 
after ischaemic stroke is actually a protective mechanism of the brain to 
maintain the cerebral blood flow. By non judicious use of 
antihypertensives we may be duing more harm to the brain. Hence11 
antihypertensives is to be used only if there is malignant hypertension or 
myocardial infarction or if the patient has BP more than 185/110 mm Hg 
and planned for thrombolysis. According to guidelines antihypertensive 
sto be used only if BP is more than 220/130 mm Hg. Avoid hyperthermia 
, maintain12 blood glucose level below 180 mg/dl. If cerebral oedema is 
present then 13 antioedema measures like intravenous mannitol and 
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furosemide may be needed. Sometimes craniotomy may be needed if 
there is severe raised intracranial tension. 
 
THROMBOLYSIS 
    The golden period upto which intravenous thrombolysis can be 
done is still a matter of debate. In our hospital the 14golden period is upto 
4.5 hours. 
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ENDOVASCULAR REVASCULARISATION 
Many a times intravascular thrombolysis may not be sufficient if 
the clot is very big. Hence studies have been conducted to find better 
methods. Mechanical thrombus removing devices and intra-arterial 
thrombolysis have all been tried but these facilities are not available in all 
centres. 15 Intra-arterial thrombolysis has not shown much benefit than 
intravenous therapy. 
 
ANTITHROMBOTIC AGENTS 
ANTIPLATELETS- 
    Aspirin has shown benefit in stroke. No other antiplatelets have 
shown much of a benefit. 
 
ANTICOAGULANTS- 
    Many studies show there is no much benefit, both long and short 
term , for anticoagulation in acute ischaemic CVA. Heparin may be used 
in case the patient has atrial fibrillation, in embolic stroke, cortical vein 
thrombosis, and for prevention of DVT in chronic bedridden patients. 
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NEUROPROTECTION 
Several animal studies have shown benefit by using16 
neuroprotective agents. However in humans perhaps because the body 
and mechanisms are more complex it has failed to show any much 
benefit. Most of these neuroprotective agents are ones that try to protect 
the ischaemic neurons in brain and decrease the excitatory 
neurotransmitters in brain. 
 
REHABILITATION 
Most of the stroke patients are left with residual disability. Hence 
physical, occupational, psychological , speech therapy and rehabilitation 
is needed and is of utmost importance. 
 
PREVENTION OF STROKE 
Control of hypertension:- 
    Reduction of both systolic and diastolic blood pressure is of value 
in reducing the risk of stroke.risk17 of CVA increased by 46% for every 
7.5 mm Hg increase in diastolic blood pressure. On an average reduction 
of blood pressure by 5.8 mm Hg decreased the risk of CVA by 42%. 
Though in the earlier times it was thought that only diastolic blood 
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pressure is important in stroke prevention but later it was proved that both 
systolic and diastolic are important. Usually a BP less than 130/80 mm 
Hg is targeted for CVA prevention. 
 
Cessation of smoking:- 
    Studies have shown that there is increased risk of stroke if the 
patient smokes. The risk rises as the number of cigarettes smoked 
increases. 18Once a patient stops smoking for 5 years the risk of CVA is 
same as a person who has not smoked at all. This is strikingly similar to 
the coronary artery disease and smoking association. 
 
Increased physical activity:- 
   Exercise is of proven benefit in stroke. It aids in reducing body 
weight, control of high blood pressure, blood glucose and hyperlipidemia. 
Many studies have shown an increased incidence of stroke associated 
with physical inactivity. Even moderate level of activity may be 
beneficial. Hence as physicians we must encourage our patients for 
weight reduction and increased physical activity, exercise to be included 
in daily routine. 
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Anticoagulation 
    As mentioned earlier atrial fibrillation increases the risk of stroke 
by nearly 5 times. It is also observed that the patients with atrial 
fibrillation are at increased risk of recurrent stroke. Hence such patients 
with19 atrial fibrillation must be placed on life long anticoagulation with 
warfarin and the target of PT INR must  be between 2 to 3. 
 
Antiplatelets 
    After an episode of stroke or transient ischaemic attack the patient 
must take Aspirin for further prevention. Other drugs like 20Clopidogrel 
and Ticlopidine have shown benefit. But these are not used much in 
clinical practice. 
 
Surgery 
    Carotid stenosis correction by surgical endarterectomy was studied 
in various studies. It was found to be beneficial in patients with 
symptomatic21 stenosis more than 70%. But the benefit of surgery in 
patients without any symptoms still remains a matter of debate and 
controversy. Other surgical options studied includeballoon angioplasty 
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with stenting and bypass surgery. However practically these methods are 
rarely used. 
 
Lipid lowering agents 
    Studies have shown beneficial role for statin use in prevention of 
stroke. Hence statins are routinely prescribed after the occurrence of 
CVA. It is found to stabilize the atherosclerotic plaque, exert beneficial 
effects on clotting and improve endothelial function. Thus very useful for 
the purpose. 
 
Folic acid 
   High homocystein levels have been linked both to increased risk of 
stroke as well as myocardial infarction. Addition of folic acid is found to 
reduce homocystein levels and thus exert beneficial effect for stroke 
prevention. 
       All these measures should be given due consideration and applied 
in daily clinical practice especially to those patients with high risk of 
stroke. Our aim should always be prevention is better than cure especially 
when it comes to CVA where the morbidity and mortality is considerably 
high. 
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C REACTIVE PROTEIN 
 
      C reactive protein is an acute phase protein that is produced in the 
liver. As the picture shows it is a pentameric structure and is ring shaped. 
It has a molecular weight of 115 kDa. Since it is an acute phase reactant it 
increases in the blood in response to inflammation. It is named so because 
it was first identified during acute inflammation in response to 
pneumococcal infection and it reacted with the c carbohydrate antigen of 
the organism.  Initially it was thought to be a pathogenic substance 
produced in the body in response conditions like malignancy, however 
this concept was later changed. Nowadays it is viewed as a marker of 
inflammation.  
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      CRP causes activation of various complement proteins and thus 
play a role in inflammatory response of body. It usually rises after 2 hours 
of inflammation and peaks in 48 hours. It has a half life of 18 hours. 
Various studies have been conducted to study the role of C reactive 
protein in the diagnosis and prognosis of various diseases. 
     The value of less than 10 mg/ dl may be taken as normal for CRP. 
Earlier we had assay that used to measure CRP but later on better 
laboratory techniques have made to detect even very low level of crp i.e 
even in the normal range called hs CRP or highly sensitive CRP. So 
nowadays we have assays to measure hs CRP. The normal range of hs 
CRP is less than 3 mg/ dl ; that can again be divided into less than 1mg / 
dl ; 1 – 3 mg / dl ; >3 mg / dl depending on the cardiac risk associated 
with the elevation of hs CRP.  
      As already mentioned CRP is an important biomarker of 
inflammation. Atherosclerosis is a state of chronic inflammation ; hence 
it a may be associated with elevated CRP. Thus CRP can be an important 
predictor of vascular events.  
     Most cases of acute ischaemic stroke may be associated with an 
elevated CRP. The22 rise in CRP following acute ischaemic CVA is due 
to the inflammation and tissue damage associated with it. There are 
various studies that tried to find the association between CRP and CVA. 
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All of them found that an increased level of CRP is associated with poor 
outcome in ischaemic cerebrovascular accident be it short or long term. 
Some studies even showed that higher CRP values even point towards a 
risk of recurrence of CVA. Hence practically we can use CRP for 
prognosticative purpose for our patients. Some studies also found that 
there is no much correlation between CRP and haemorrhagic 
cerebrovascular accident23. 
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MATERIALS AND METHODS 
The study was conducted at the department of Internal Medicine, 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai 600003. 
 
ETHICAL COMMITTEE APPROVAL 
Obtained 
 
PATIENT CONSENT  
Obtained 
 
DURATION OF STUDY 
6 months 
 
STUDY DESIGN 
Observational study 
 
SAMPLE SIZE  
100 patients 
40 
 
INCLUSION CRITERIA 
Patients 
• 18-60 years  
• Diagnosed as first episode of Acute  ischaemic stroke admitted in 
medical wards .  
 
EXCLUSION CRITERIA 
• Pregnant women 
• Haemorrhagic stroke 
• Cortical venous thrombosis 
• Recurrent stroke 
• Traumatic brain injury 
• Autoimmune diseases 
• Recent acute coronary syndrome 
• Chronic renal failure 
• Liver cell failue 
• Infectious diseases 
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DATA COLLECTION AND METHODOLOGY 
          Patients are subjected to detailed history taking and clinical 
examination. 
Patients admitted with acute ischaemic stroke - selected for clinical 
study as per inclusion / exclusion criteria  are subjected to routine blood 
investigations like complete hemogram, renal function tests, serum 
electrolytes, liver function test, S.CRP, CT Brain. Detailed history taking 
and  clinical examination will be done. Patients with acute ischaemic 
stroke will be analysed for following factors  
            - Age 
            - sex 
            - diabetic or hypertensive 
            - dyslipidemia 
            - history of smoking 
            - onset and duration of weakness 
Stroke will be categorized as mild,moderate and severe using 
National Institute of Health Stroke Scale( NIHSS).Patients  will be 
followed up for outcome at the time of discharge using modified Rankin 
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Scale(mRS) and Barthel Index(BI) .Poor outcome considered to be 
>2mRS score and <95 BI.Serum CRP will be correlated with severity and 
outcome. 
STATISTICAL ANALYSIS 
The results are analysed using SPSS software version 20. 
Association between variables were analysed using chi-square test. The 
primary association expected was C reactive protein and severity of 
stroke. Hence both were compared and also with the outcome of stroke at 
discharge. 
Statistical significance is assumed with a p value of less than 0.005 
 
SPONSORSHIP 
No 
 
CONFLICT OF INTEREST 
None 
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OBSERVATION AND RESULTS 
PATIENTS 
 
NIHSS Total 
Mild Moderate Severe  
 Male  Count 20 29 17 66 
  
 
 
% within 
Gender 
 
 
30.3% 43.9% 25.8% 100.0% 
  
 
% within 
NIHSS 
48.8% 78.4% 77.3% 66.0% 
 Female 
 
Count 
 
21 8 5 34 
 
 
 
 
 
% within 
Gender 
 
61.8% 23.5% 14.7% 100.0% 
  
 
% within 
NIHSS 
51.2% 21.6% 22.7% 34.0% 
 
Total 
 
Count 
 
41 37 22 100 
 
% within 
Gender 
 
41.0% 37.0% 22.0% 100.0% 
 
% within 
NIHSS 100.0% 100.0% 100.0% 100.0% 
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SEX DISTRIBUTION 
MALE       
FEMALE 
66% 
34% 
 
45 
 
 
 
  As the age of the patient increases the severity of stroke increases 
as observed in the study. 
 
 
 
Age in years
51-6041-5031-40
Co
u
n
t
30
20
10
0
NIHSS
Mild
Moderate
Severe
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In our study most of the patients were male. Males were found to 
have severe stroke compared to females. 
 
 
Gender
FemaleMale
Co
u
n
t
40
30
20
10
0
NIHSS
Mild
Moderate
Severe
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SMOKING AND STROKE 
 
 
NIHSS Total 
Mild Moderate Severe  
Smoking Yes 
Count 
 
10 23 17 50 
  
% within    
Smoking 
 
20.0% 46.0% 34.0% 100.0% 
  
% within 
NIHSS 
 
24.4% 62.2% 77.3% 50.0% 
 No 
Count 
 
31 14 5 50 
  
% within 
Smoking 
 
62.0% 28.0% 10.0% 100.0% 
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Most of the patients who had not smoked developed mild stroke 
compared to the patients who had smoked. P value was less than 0.001 
hence statistically significant. 
 
  
% within 
NIHSS 
 
75.6% 37.8% 22.7% 50.0% 
Total 
Count 
 
41 37 22 100 
 
% within 
Smoking 
 
41.0% 37.0% 22.0% 100.0% 
 
% within 
NIHSS 
100.0% 100.0% 100.0% 100.0% 
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Smoking
NoYes
Co
u
n
t
40
30
20
10
0
NIHSS
Mild
Moderate
Severe
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BLOOD PRESSURE AND STROKE 
 
Blood Pressure 
 
NIHSS 
Total 
 
 
P value Mild 
Modera
te 
Severe 
 Normal Count 23 16 3 42 0.002 
  
% within 
Blood 
Pressure 
 
54.8% 38.1% 7.1% 100.0%  
  
% within 
NIHSS 
 
56.1% 43.2% 13.6% 42.0%  
 Abnormal 
Count 
 
18 21 19 58  
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% within 
Blood 
Pressure 
 
31.0% 36.2% 32.8% 100.0%  
  
% within 
NIHSS 
 
43.9% 56.8% 86.4% 58.0%  
Total 
Count 
 
41 37 22 100  
 
% within 
Blood 
Pressure 
 
41.0% 37.0% 22.0% 100.0%  
 
% within 
NIHSS 
100.0% 100.0% 100.0% 100.0%  
 
Most of the patients who developed stroke were hypertensive. 
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Blood Pressure
AbnormalNormal
Co
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n
t
30
20
10
0
NIHSS
Mild
Moderate
Severe
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STROKE AND RANDOM BLOOD SUGAR 
Random blood sugar 
NIHSS 
Total 
 
 
P value Mild 
Modera
te 
Severe 
 Normal 
Count 
 
31 21 5 57  
  
% within 
Random 
blood sugar 
 
54.4% 36.8% 8.8% 100.0% 
Less 
than 
0.001 
  
% within 
NIHSS 
 
75.6% 56.8% 22.7% 57.0%  
 
Abnorma
l 
Count 
 
10 16 17 43  
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% within 
Random 
blood sugar 
 
23.3% 37.2% 39.5% 100.0%  
  
% within 
NIHSS 
 
24.4% 43.2% 77.3% 43.0%  
Total 
Count 
 
41 37 22 100  
 
% within 
Random 
blood sugar 
 
41.0% 37.0% 22.0% 100.0%  
 
% within 
NIHSS 
100.0% 100.0% 100.0% 100.0%  
 
Patients with elevated random blood sugar suffered severe stroke. 
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Random blood sugar
AbnormalNormal
Co
u
n
t
40
30
20
10
0
NIHSS
Mild
Moderate
Severe
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STROKE AND SERUM CHOLESTEROL 
 
Serum 
Cholesterol 
 NIHSS 
Total 
 
 
P value 
 Mild 
Modera
te 
Severe 
 Normal 
Count 
 
21 11 4 36  
  
% within 
Serum 
Cholesterol 
 
58.3% 30.6% 11.1% 100.0% 0.019 
  
% within 
NIHSS 
 
51.2% 29.7% 18.2% 36.0%  
 Abnormal 
Count 
 
20 26 18 64  
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% within 
Serum 
Cholesterol 
 
31.3% 40.6% 28.1% 100.0%  
  
% within 
NIHSS 
 
48.8% 70.3% 81.8% 64.0%  
Total 
Count 
 
41 37 22 100  
 
% within 
Serum 
Cholesterol 
 
41.0% 37.0% 22.0% 100.0%  
 
% within 
NIHSS 
100.0% 100.0% 100.0% 100.0%  
  
Most (64%) of the patients who developed stroke had high serum 
cholesterol. 
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Serum Cholesterol
AbnormalNormal
Co
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n
t
30
20
10
0
NIHSS
Mild
Moderate
Severe
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STROKE AND C REACTIVE PROTEIN 
 
In our study males had an average higher CRP value compared to 
females with ischaemic stroke. 
 
In our study those who smoked had a higher CRP value compared 
to non smokers with ischaemic stroke. 
 Gender N Mean 
Std. 
Deviation 
Std. Error 
Mean 
P value 
CRP Male 66 45.50 33.266 4.095 
0.02 
 Female 34 29.44 32.697 5.608 
 Smoking N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
P value 
CRP Yes 50 54.24 34.352 4.858 Less than 
0.001 
 No 50 25.84 26.730 3.780 
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Blood 
Pressure 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
 
P value 
CRP Normal 42 29.10 26.319 4.061 
0.003 
 Abnormal 58 47.97 36.497 4.792 
 
In our study higher CRP values were found in hypertensive 
patients with stroke. 
 
 
Random 
blood sugar 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
 
P value 
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In our study stroke patients with abnormal random blood sugar had 
higher mean CRP values. 
 
In our study stroke patients with abnormal serum cholesterol had 
higher mean CRP values. 
 
 
CRP Normal 57 29.46 28.821 3.817 
Less 
than 
0.001 
 Abnormal 43 54.07 35.062 5.347  
 
Serum 
Cholesterol 
N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
 
P value 
CRP Normal 36 32.69 31.548 5.258 0.002 
 Abnormal 64 44.17 34.533 4.317  
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 MRS N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
P value 
CRP Good 39 8.85 2.651 .425  
 Poor 61 59.98 29.017 3.715 
Less than 
0.001 
 
 
From the study it was found that stroke patients with a mean CRP 
of 8.85 had a good prognosis according to modifies rankin score. Those 
patients with a mean CRP of 59.98 had poor prognosis. Similar outcome 
was obtained using barthel index ; where the mean CRP was 8.13 for 
good prognosis and 54.38 for bad prognosis. 
 BI N Mean 
Std. 
Deviation 
Std. Error 
Mean 
 
P value 
CRP Good 31 8.13 2.232 .401  
 Poor 69 54.38 31.412 3.782 
Less than 
0.001 
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The study showed that the mean CRP values for mild stroke was 
10.85 ; moderate stroke 42.19 ; and for severe stroke was 90.82. Thus 
higher the CRP values more severe the stroke.this was found to be 
statistically significant using ANOVA , P value being less than 0.001 
 
 
 
 N Mean 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minim
um 
Maxim
um 
     
Lower 
Bound 
Upper 
Bound 
  
Mild 41 10.85 10.355 1.617 7.59 14.12 5 70 
Moderat
e 
37 42.19 17.211 2.829 36.45 47.93 18 72 
Severe 22 90.82 17.215 3.670 83.19 98.45 60 118 
Total 100 40.04 33.784 3.378 33.34 46.74 5 118 
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The study showed a higher value of CRP in older age group 
patients with stroke. The p value was 0.002 and statistically significant. 
 
Age N Mean 
Std. 
Deviati
on 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minim
um 
Maxim
um 
     
Lower 
Bound 
Upper 
Bound 
  
31-40 
 
12 29.42 21.707 6.266 15.62 43.21 7 63 
41-50 
 
34 34.38 31.546 5.410 23.38 45.39 6 104 
51-60 
 
54 45.96 36.507 4.968 36.00 55.93 5 118 
Total 100 40.04 33.784 3.378 33.34 46.74 5 118 
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This chart clearly shows that stroke patients with higher values of 
CRP had more severe stroke according to NIHSS. 
 
 
NIHSS
SevereModerateMild
CR
P
100
80
60
40
20
0
66 
 
 
 
This chart shows that stroke patients with higher CRP values had 
poorer outcome compared to those with lower values of CRP. 
 
 
 
 
Barthel Index
PoorGood
CR
P
60
50
40
30
20
10
0
67 
 
 
 
This chart shows that stroke patients with higher values of CRP 
had poorer outcome than with lower values of CRP according to modified 
rankin score. 
 
 
Modified Rankin Score
PoorGood
CR
P
70
60
50
40
30
20
10
0
68 
 
  CRP 
Age in years 
Pearson Correlation .210(*) 
Sig. (2-tailed) .036 
N 100 
SBP 
Pearson Correlation .359(**) 
Sig. (2-tailed) .000 
N 100 
DBP 
Pearson Correlation .193 
Sig. (2-tailed) .055 
N 100 
Random blood sugar 
Pearson Correlation .418(**) 
Sig. (2-tailed) .000 
N 100 
Serum Cholesterol 
Pearson Correlation .236(*) 
Sig. (2-tailed) .018 
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N 100 
NIHSS 
Pearson Correlation .916(**) 
Sig. (2-tailed) .000 
N 100 
MRS 
Pearson Correlation .861(**) 
Sig. (2-tailed) .000 
N 100 
BI 
Pearson Correlation -.922(**) 
Sig. (2-tailed) .000 
N 100 
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Descriptive statistics 
 N Minimum Maximum Mean 
Std. 
Deviation 
Age in years 100 32 60 51.21 7.568 
SBP 100 110 184 142.28 23.960 
DBP 100 70 100 84.70 7.714 
Random blood sugar 100 112 300 198.82 57.944 
Serum Cholesterol 100 112 280 215.82 47.555 
CRP 100 5 118 40.04 33.784 
NIHSS 100 1 20 10.18 4.883 
MRS 100 1 5 3.11 1.442 
BI 100 30 100 73.90 23.832 
Valid N (listwise) 100     
 
This summarises the various variables used in the study and their 
ranges. 
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DISCUSSION 
An observational study was conducted at The Institute of Internal 
Medicine at Madras Medical College and Rajiv Gandhi Government 
General Hospital , Chennai 600003 for a period of 6 months. 
      100 patients admitted with acute ischaemic stroke were selected for 
the study. These patients were assessed at the time of admission by a 
detailed history taking giving due importance to smoking history, 
comorbidities like diabetes, hypertension, dyslipidemia etc. A thorough 
clinical examination was done for the patients which included general 
examination, vitals, neurological examination and other system 
examination. Patients were then categorised into mild, moderate and 
severe using the clinical National Institute of Health Stroke Scale 
(NIHSS). Routine blood investigations like complete haemogram , renal 
function test, liver function test were done. Apart from these lipid profile, 
random blood sugar, C reactive protein, and CT brain were done. Patients 
blood reports were followed up and then after a week at the time of 
discharge of the patients they were again clinically assessed for the 
outcome using Modified Rankin Score (MRS) and Barthel Index (BI). 
        The results obtained were analysed using various statistical tests like 
chi-square , ANOVA and p value were obtained. 
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 In a study conducted by M.A Shoeb, M .A Shehata et al 50 patients 
with new onset acute ischaemic stroke were included. They were assessed 
clinically and graded into mild moderate and severe according to NIHSS 
score. Blood samples were sent for routine investigations and CRP.  
Outcome was assessed after a week using Modified Rankin Score and 
Barthel Index. They found out that serum CRP was indicative of stroke 
severity and correlated with the prognosis of stroke as the p value was 
less than 0.001 indicating it to be statistically very significant. 
     After analysing the various variables of our study many 
observations were made. Our study had more number of males , 66% 
males and 34% females. More percent of males were found to have 
severe stroke compared to females probably because many of the males 
were smokers and smoking is a risk factor for stroke. Correlation of age 
and stroke showed that severe stroke occurred in older age group 
compared to younger patients. Severe stroke patients were found to be 
hypertensive and they also had elevated blood sugar and serum 
cholesterol values. All these correlations had a p value less than 0.05 and 
hence statistically significant. Study also showed that smokers, 
hypertensive, diabetic and patients with dyslipidemia had higher mean 
CRP values. This was also found to be statistically significant. The mean 
CRP values for mild stroke was found to be 10.85 mg / dl, moderate was 
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42.19 mg / dl , severe was 90.82 mg / dl. The p value was less than 0.001. 
Higher crp values had severe stroke. Outcome measured by Modified 
Rankin Score showed that a CRP values less than 8.85 mg/ dl had good 
prognosis. Using Barthel Index CRP values less than 8.13 mg / dl had 
good prognosis. Both the correlations were statistically highly significant 
as P value were less than 0.001. 
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LIMITATIONS OF THE STUDY 
• A multicentric and larger study may be needed to prove the 
correlation. 
 
• There may be variations in the various methods of measurements 
of CRP from one laboratory to other. 
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CONCLUSION 
 
• A higher value of C reactive protein is a predictor of severe 
disease. 
 
• A higher values of C reactive protein on admission is a predictor of 
poor prognosis for stroke. 
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“CRP IN ACUTE ISCHAEMIC STROKE: Prognostic Implications” 
PROFORMA 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
 
Weakness of  upper and lower limbs 
Slurring of  speech 
 
 
PAST HISTORY: 
 
DM  
HTN  
DYSLIPIDEMIA  
CAD  
CKD  
CLD  
 
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
GENERAL EXAMINATION: 
 
GCS  
 
VITAL SIGNS: 
       PR- 
       BP- 
       RR- 
       TEMP- 
SYSTEMIC  EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 RIGHT LEFT 
HIGHER MENTAL 
FUNCTIONS 
 
 
 
 
CRANIAL NERVES 
      Olfactory  
      Optic 
      Oculomotor   
      Trochlear            
      Abducent 
  
      Trigemenal 
      Facial 
      Vestibulocochlear 
      Glossopharyngeal 
      Vagus 
      Spinal accessory 
      Hypoglossal 
 
MOTOR  
  
BULK:UL 
                LL 
  
 TONE:UL 
              LL 
      
  
POWER:UL 
                LL 
  
 
REFLEX:UL 
                 LL 
 
  
PLANTAR 
 
  
 
  
SENSORY EXAMINATION: 
 
 
 
CEREBELLAR SIGNS: 
 
 
 
SIGNS OF MENINGEAL IRRITATION: 
 
 
 
 
 
 
INVESTIGATIONS 
 
COMPLETE  HEMOGRAM 
 
RFT 
 
SERUM  ELECROLYTES 
 
LFT 
 
ECG 
 
SERUM  CRP 
 
CT BRAIN 
 
 
 
 
                                  
 
 
  
  
TURNITIN PLAGIARISM SCREENSHOT 
  
DIGITAL RECEIPT  
 
  
INFORMATION SHEET 
We are conducting a study on “CRP IN ACUTE ISCHAEMIC 
STROKE : PROGNOSTIC IMPLICATIONS” among patients admitted in 
EMERGENCY MEDICINE DEPARTMENT in Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to us. 
           The purpose of this study is to assess the ROLE OF C REACTIVE 
PROTEIN IN PREDICTING THE SEVERITY AND OUTCOME IN ACUTE 
ISCHEMIC STROKE PATIENTS. 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do certain tests which in any way do not affect 
your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment 
 
 Signature of Investigator     Signature of Participant 
Date: 
   
PATIENT CONSENT FORM 
Study Detail : “CRP IN ACUTE ISCHAEMIC STROKE : 
PROGNOSTIC IMPLICATIONS” 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for 
the above study. I have the opportunity to ask question and all 
my questions and doubts have been answered to my complete 
satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time without giving reason, 
without my legal rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working 
on the sponsor’s behalf, the ethical committee and the 
regulatory authorities will not need my permission to look at 
my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if 
I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any 
information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any 
data or results that arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate 
with the study team and to immediately inform the study staff 
if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical 
examination and blood investigations as required. ❏ 
 
 
SIGNATURE OF INVESTIGATOR                       
SIGNATURE/THUMB IMPRESSION 
 
STUDY INVESTIGATOR’S    PATIENT’S NAME AND 
NAME:               ADDRESS: 
 
DR.RENJINI RADHAKRISHNAN  
  
  
KEY TO MASTER CHART 
 
BP   -  Blood Pressure 
RBS    -  Random Blood Sugar 
CRP   -  C Reactive Protein 
NIHSS -  National Institute of Health Stroke Scale 
MRS   -  Modified Rankin Score 
BI   - Barthel Index 
 
